View in EDS

Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models.

Saved in:
Bibliographic Details
Title: Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models.
Authors: Xu C; Immuno-Oncology Translational Innovation Platform, EMD Serono Research and Development Institute, Billerica, Massachusetts. Chunxiao.xu@emdserono.com yan.lan@emdserono.com., Zhang Y; Immuno-Oncology Translational Innovation Platform, EMD Serono Research and Development Institute, Billerica, Massachusetts., Rolfe PA; Immuno-Oncology Translational Innovation Platform, EMD Serono Research and Development Institute, Billerica, Massachusetts., Hernández VM; Immuno-Oncology Translational Innovation Platform, EMD Serono Research and Development Institute, Billerica, Massachusetts., Guzman W; Immuno-Oncology Translational Innovation Platform, EMD Serono Research and Development Institute, Billerica, Massachusetts., Kradjian G; Immuno-Oncology Translational Innovation Platform, EMD Serono Research and Development Institute, Billerica, Massachusetts., Marelli B; Immuno-Oncology Translational Innovation Platform, EMD Serono Research and Development Institute, Billerica, Massachusetts., Qin G; Immuno-Oncology Translational Innovation Platform, EMD Serono Research and Development Institute, Billerica, Massachusetts., Qi J; Immuno-Oncology Translational Innovation Platform, EMD Serono Research and Development Institute, Billerica, Massachusetts., Wang H; Immuno-Oncology Translational Innovation Platform, EMD Serono Research and Development Institute, Billerica, Massachusetts., Yu H; Immuno-Oncology Translational Innovation Platform, EMD Serono Research and Development Institute, Billerica, Massachusetts., Tighe R; Immuno-Oncology Translational Innovation Platform, EMD Serono Research and Development Institute, Billerica, Massachusetts., Lo KM; Immuno-Oncology Translational Innovation Platform, EMD Serono Research and Development Institute, Billerica, Massachusetts., English JM; Immuno-Oncology Translational Innovation Platform, EMD Serono Research and Development Institute, Billerica, Massachusetts., Radvanyi L; Immuno-Oncology Translational Innovation Platform, EMD Serono Research and Development Institute, Billerica, Massachusetts., Lan Y; Immuno-Oncology Translational Innovation Platform, EMD Serono Research and Development Institute, Billerica, Massachusetts. Chunxiao.xu@emdserono.com yan.lan@emdserono.com.
Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2017 Oct 01; Vol. 23 (19), pp. 5869-5880. Date of Electronic Publication: 2017 Jul 05.
Publication Type: Clinical Trial, Phase I; Journal Article
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1557-3265
DOI:10.1158/1078-0432.CCR-17-0483